Peripheral Vascular Research: Camper Trial: Drug Research offered after Peripheral Angioplasty and/or Stent Placement

Study of:
The CAMPER trial compares the effects of Clopidegrel (Plavix) and aspirin vs. placebo and aspirin in patients being treated with a balloon procedure (angioplasty) and or stent in their lower extremity. Clopidegrel is a blood thinning drug that has been approved by the FDA.

Patients who meet inclusion criteria will be randomized within three hours after their procedure to receive the loading dose of clopidrogrel (Plavix) vs. a placebo with low dose (81-162 mg) aspirin. Patients will continue on the study drug vs. placebo for the remainder of the study.

Entry Criteria:
Inclusion

• Age greater than 40 years old
• Evidence of peripheral arterial disease prior to angioplasty/stent procedure

Exclusion

• History of bleeding problems
• Heart attack or stroke in last 3 months
• Low platelet count
• Uncontrolled high blood pressure
• Patients on coumadin or heparin

Study Requirements:

• Follow up will include 1, 6, 12, 18, 24, and 30-month visits.
• Assessments include labs, ultrasound, ECG, and physical exams.

• Yale Wang, MD, FACC, FSCAI

• Daniel Lips, MD, FACC

• Denise Windenburg, CCRC

For more information about this study or other research studies at the Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, please contact Denise Windenburg at 612-863-3816.